Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
NEW YORK - Scienture Holdings, Inc. (NASDAQ:SCNX) has regained compliance with Nasdaq’s minimum bid price requirement after its stock traded above $1.00 per share for ten consecutive business days, the company announced Wednesday. The stock currently trades at $1.71, showing strong momentum with a 6.9% gain in the past week, though it remains well below its 52-week high of $13.42.
The pharmaceutical holding company had received a notification from Nasdaq on May 19, 2025, stating that it was not in compliance with the exchange’s listing rule requiring a minimum bid price of $1.00 per share. At that time, Scienture was given until November 17, 2025, to meet the requirement. According to InvestingPro data, the stock has experienced significant volatility, with an 85.6% decline over the past year.
"We are pleased with the efforts of our team to regain compliance with Nasdaq Listing Rule 5550(a)(2) and ensure that our common stock will continue to be listed on Nasdaq," said Shankar Hariharan, Co-Chief Executive Officer and Executive Chairman of the company.
Narasimhan Mani, Co-Chief Executive Officer and President, noted that regaining compliance allows the company to "place our full attention on our upcoming product launches," including their first FDA-approved product, Arbli.
Scienture Holdings operates through its wholly owned subsidiaries, including Scienture, LLC, and focuses on developing specialty pharmaceutical products. The company aims to satisfy unmet market needs across various therapeutic areas. InvestingPro analysis reveals concerning metrics, including rapid cash burn and weak gross profit margins of 4.55%. Subscribers can access 8 additional key insights about SCNX’s financial health and market position.
The information in this article is based on a press release statement from Scienture Holdings.
In other recent news, Scienture Holdings has terminated its Equity Line of Credit (ELOC) facility, effective May 22, 2025. The company filed a post-effective amendment to deregister all 310,488 unsold shares of common stock that were previously registered under the facility. This decision is part of a strategic financial move as Scienture prepares for the commercial launch of Arbli, its FDA-approved oral liquid losartan product, slated for the third quarter of 2025. Co-Chief Executive Officer and Executive Chairman Shankar Hariharan stated that this move allows management to focus on the planned commercialization of Arbli. Co-Chief Executive Officer and President Naraismhan Mani emphasized the company’s commitment to finding more favorable funding opportunities to support its strategic plans. Arbli is designed to treat hypertension, reduce stroke risk, and address diabetic nephropathy in certain patients. The product is notable for being the first and only oral liquid formulation of losartan approved by the U.S. FDA.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.